This document summarizes two feasibility studies testing the nebulization of OSCN- and lactoferrin (Meveol) for cystic fibrosis patients. One study evaluated different nebulizers and found the Aeroneb Go/Idehaler-Pocket combination achieved the highest inhalable fraction. The other study showed Meveol inhibited various bacteria, including a 1.6 log reduction of Pseudomonas aeruginosa in mouse lungs. Overall, the studies demonstrate Meveol's potential as an inhaled antimicrobial treatment for cystic fibrosis infections when delivered by a mesh nebulizer.